| Identification | Back Directory | [Name]
DCC-3116 | [CAS]
2661481-41-8 | [Synonyms]
DCC-3116
(R)-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-fluoro-8-methyl-8-(trifluoromethyl)-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine-6-carboxamide
6H-Pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine-6-carboxamide, N-[5-chloro-6-(2H-1,2,3-triazol-2-yl)-3-pyridinyl]-2-fluoro-7,8-dihydro-8-methyl-8-(trifluoromethyl)-, (8R)- | [Molecular Formula]
C18H12ClF4N9O | [MOL File]
2661481-41-8.mol | [Molecular Weight]
481.79 |
| Hazard Information | Back Directory | [Uses]
SGR-1505 is an orally active MALT1 allosteric inhibitor. SGR-1505 inhibits MALT1 enzymatic activity and shows anti-proliferative activity in BTK inhibitor (BTKi)-sensitive and BTKi-resistant activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) cell lines. SGR-1505 can be used for research of B-cell lymphomas[1]. | [References]
[1] Adam Olszewski MD, et al. A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of Sgr-1505 As Monotherapy in Subjects with Mature B-Cell Malignancies.Blood. Volume 142, Supplement 1, 2 November 2023, Page 3102.
[2] Feng S, et al., Cyclic compounds and methods of using same. WO2021134004. |
|
|